1-4 of 4
Neil H. Segal
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B207: Nivolumab +/- Ipilimumab in patients with hypermutated cancers detected in blood: NIMBLE

Free
Naiyer Rizvi, Patricia Tang, Nina Bhardwaj, Timothy A. Chan, Jeffrey S. Weber, Michael Vickers, Sofya Pintova, Holger Hirte, Neil H. Segal, Neesha Dhani, Daniel Cho, Stephen Chia, Caitlin Burns, Donsheng Tu, Laura Pearce, Alison Urton, Martin Smoragiewicz, Janet Dancey
Journal: Cancer Immunology Research
Cancer Immunol Res (2019) 7 (2_Supplement): B207.
https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR18-B207
Published: 01 February 2019
View articletitled, Abstract B207: Nivolumab +/- Ipilimumab in patients with hypermutated cancers detected in blood: NIMBLE
Journal Articles

A Blueprint to Advance Colorectal Cancer Immunotherapies

Free
Dung T. Le, Vanessa M. Hubbard-Lucey, Michael A. Morse, Christopher R. Heery, Andrea Dwyer, Thomas H. Marsilje, Arthur N. Brodsky, Emily Chan, Dustin A. Deming, Luis A. Diaz, Jr, Wolf H. Fridman, Richard M. Goldberg, Stanley R. Hamilton, Franck Housseau, Elizabeth M. Jaffee, S. Peter Kang, Smitha S. Krishnamurthi, Christopher H. Lieu, Wells Messersmith, Cynthia L. Sears, Neil H. Segal, Arvin Yang, Rebecca A. Moss, Edward Cha, Jill O'Donnell-Tormey, Nancy Roach, Anjelica Q. Davis, Keavy McAbee, Sharyn Worrall, Al B. Benson
Journal: Cancer Immunology Research
Series: Author Choice
Cancer Immunol Res (2017) 5 (11): 942–949.
https://doi.org/10.1158/2326-6066.CIR-17-0375
Published: 31 October 2017
View articletitled, A Blueprint to Advance Colorectal Cancer Immunotherapies
Open the PDF for A Blueprint to Advance Colorectal Cancer Immunotherapies in another window
Includes: Supplementary data
Journal Articles

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1

Free
Jarushka Naidoo, Katja Schindler, Christiane Querfeld, Klaus Busam, Jane Cunningham, David B. Page, Michael A. Postow, Alyona Weinstein, Anna Skripnik Lucas, Kathryn T. Ciccolini, Elizabeth A. Quigley, Alexander M. Lesokhin, Paul K. Paik, Jamie E. Chaft, Neil H. Segal, Sandra P. D'Angelo, Mark A. Dickson, Jedd D. Wolchok, Mario E. Lacouture
Journal: Cancer Immunology Research
Cancer Immunol Res (2016) 4 (5): 383–389.
https://doi.org/10.1158/2326-6066.CIR-15-0123
Published: 01 May 2016
View articletitled, Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1
Open the PDF for Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1 in another window
Journal Articles

Abstract A047: Safety and clinical activity of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)

Free
Scott Antonia, Naiyer Rizvi, Julie Brahmer, Sai-Hong Ou, Samir N. Khleif, Wen-Jen Hwu, Martin Gutierrez, Patrick Schoffski, Omid Hamid, Jared Weiss, Jose Lutzky, Michele Maio, John Nemunaitis, Dirk Jaeger, Ani Balmanoukian, Marlon C. Rebelatto, Keith E. Steele, Xiaoping Jin, Paul B. Robbins, John A. Blake-Haskins, Neil H. Segal
Journal: Cancer Immunology Research
Cancer Immunol Res (2016) 4 (1_Supplement): A047.
https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR15-A047
Published: 03 January 2016
View articletitled, Abstract A047: Safety and clinical activity of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)